Still, the FDA has not approved retatrutide yet, and patients should not use online or compounded versions
Its definitely a common thing that were seeing in the office, said Marisa Garshick, MD, a board certified dermatologist and clinical assistant professor of dermatology at Weill Cornell Medicine
"I think one of the things that needs to be understood is that a GLP-1 agonist, whether it's for weight loss or diabetes, it is meant to be on for a while, this is a long-term therapy
Another Harvard-led study found a 29% increase in coronary heart disease risk for each 0.5-point increase in HbA1c above 5.0%. In practical terms, continued Dr
But that rollout has hit delays and uncertain plan participation, and as the Kaiser Family Foundation has reported, theres no guaranteed path for Medicare GLP-1 weight-loss coverage once the Bridge expires